Weight-Loss drug may cut breast cancer risk in obese women
NCT ID NCT06485089
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 30 times
Summary
This study looks at whether tirzepatide, a drug used for weight loss, can change certain markers in the blood and breast tissue that are linked to breast cancer risk. The study includes 20 women with obesity who also have other breast cancer risk factors. Researchers will measure changes in breast density and tissue health after 3-6 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Medical Center Breast Cancer Prevention Center
Westwood, Kansas, 66208, United States
Conditions
Explore the condition pages connected to this study.